((自动化翻译由路透提供，请见免责声明 ))
10月22日 - ** 远程医疗公司 Mangoceuticals （又称 MangoRx）的股票盘前上涨 2.1%，至 3.94 美元
** 公司称已启动审查程序，评估潜在的战略选择，包括但不限于潜在的合并、收购、剥离和其他交易
** MGRX 尚未确定完成审查程序的时间表
** 本周早些时候，礼来公司 起诉了包括MangoRx在内的三家医疗水疗中心和在线销售商，指控他们销售声称含有蒂氮帕肽的 (link)，蒂氮帕肽是礼来公司广受欢迎的减肥药Zepbound的主要成分。
** 该诉讼是在 MangoRx 推出名为 "Trim "的自有品牌之后发生的，"Trim "是一种复方口服可溶解替扎帕肽片剂。
** 截至上日收盘，股价累计下跌 41.5
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.